R Welte

1.5k total citations
46 papers, 1.1k citations indexed

About

R Welte is a scholar working on Microbiology, Epidemiology and General Health Professions. According to data from OpenAlex, R Welte has authored 46 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Microbiology, 18 papers in Epidemiology and 14 papers in General Health Professions. Recurrent topics in R Welte's work include Reproductive tract infections research (16 papers), Urinary Tract Infections Management (7 papers) and Bacterial Infections and Vaccines (7 papers). R Welte is often cited by papers focused on Reproductive tract infections research (16 papers), Urinary Tract Infections Management (7 papers) and Bacterial Infections and Vaccines (7 papers). R Welte collaborates with scholars based in Germany, Netherlands and Belgium. R Welte's co-authors include Reiner Leidl, Maarten J. Postma, Mirjam Kretzschmar, Talitha Feenstra, Anneke van den Hoek, Hans‐Helmut König, Katharina Buesch, J. C. Jager, Jan Bakker and Leona Hakkaart‐van Roijen and has published in prestigious journals such as American Journal of Epidemiology, Vaccine and Critical Care.

In The Last Decade

R Welte

44 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R Welte Germany 18 391 387 379 225 157 46 1.1k
Concepción Carratalá‐Munuera Spain 20 302 0.8× 167 0.4× 95 0.3× 116 0.5× 190 1.2× 111 1.4k
Yagob Al-Mazrou Saudi Arabia 19 445 1.1× 445 1.1× 67 0.2× 147 0.7× 303 1.9× 51 2.1k
Fred Were Kenya 23 357 0.9× 414 1.1× 118 0.3× 157 0.7× 316 2.0× 62 1.6k
Helen McDonald United Kingdom 24 747 1.9× 227 0.6× 223 0.6× 68 0.3× 407 2.6× 84 2.1k
Ashley B. Coffield United States 8 323 0.8× 579 1.5× 52 0.1× 302 1.3× 293 1.9× 10 1.3k
Ramón Martínez United States 19 263 0.7× 262 0.7× 67 0.2× 130 0.6× 199 1.3× 48 1.3k
Mary Linehan United States 19 432 1.1× 121 0.3× 111 0.3× 80 0.4× 117 0.7× 56 1.2k
Charles Stoecker United States 15 850 2.2× 193 0.5× 187 0.5× 167 0.7× 139 0.9× 69 1.4k
Dan Ewald Australia 15 244 0.6× 325 0.8× 60 0.2× 103 0.5× 194 1.2× 35 836
Daniel J. Isaacman United States 22 895 2.3× 187 0.5× 297 0.8× 87 0.4× 384 2.4× 47 1.6k

Countries citing papers authored by R Welte

Since Specialization
Citations

This map shows the geographic impact of R Welte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Welte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Welte more than expected).

Fields of papers citing papers by R Welte

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R Welte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Welte. The network helps show where R Welte may publish in the future.

Co-authorship network of co-authors of R Welte

This figure shows the co-authorship network connecting the top 25 collaborators of R Welte. A scholar is included among the top collaborators of R Welte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R Welte. R Welte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maywald, Ulf, et al.. (2021). Extent of non-adherence and non-persistence in asthma patients: analysis of a large claims data set. Journal of Asthma. 59(4). 829–839. 7 indexed citations
2.
3.
Marten, Ole, Florian Koerber, David E. Bloom, et al.. (2019). A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease. Health and Quality of Life Outcomes. 17(1). 87–87. 8 indexed citations
4.
Dolk, F Christiaan K, Martin Eichner, R Welte, et al.. (2016). Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model. PharmacoEconomics. 34(12). 1299–1308. 36 indexed citations
5.
Damm, Oliver, et al.. (2016). Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review. International Journal of Public Health. 61(7). 847–860. 26 indexed citations
6.
Wit, G. Ardine de, Eelco A. B. Over, Boris V. Schmid, et al.. (2015). Chlamydia screening is not cost-effective at low participation rates: evidence from a repeated register-based implementation study in the Netherlands. Sexually Transmitted Infections. 91(6). 423–429. 22 indexed citations
7.
Tan, Siok Swan, Jan Bakker, Marga Hoogendoorn, et al.. (2012). Direct Cost Analysis of Intensive Care Unit Stay in Four European Countries: Applying a Standardized Costing Methodology. Value in Health. 15(1). 81–86. 122 indexed citations
8.
Wolf, Eva, Markus Blankenburg, Johannes R. Bogner, et al.. (2010). Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany. European journal of medical research. 15(4). 145–145. 20 indexed citations
9.
Postma, Maarten J., Robin de Vries, R Welte, & W. John Edmunds. (2007). Health economic methodology illustrated with recent work on Chlamydia screening: the concept of extended dominance. Sexually Transmitted Infections. 84(2). 152–154. 11 indexed citations
10.
Welte, R, et al.. (2006). Combination Vaccine Against Invasive Meningococcal B and Pneumococcal Infections. PharmacoEconomics. 24(2). 141–153. 19 indexed citations
11.
Welte, R, et al.. (2006). Mortality, morbidity and costs attributable to smoking in Germany: update and a 10-year comparison. Tobacco Control. 15(6). 464–471. 110 indexed citations
12.
Welte, R, Caroline Trotter, W. John Edmunds, Maarten J. Postma, & Philippe Beutels. (2005). The Role of Economic Evaluation in Vaccine Decision Making. PharmacoEconomics. 23(9). 855–874. 26 indexed citations
13.
Welte, R, et al.. (2004). A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries. PharmacoEconomics. 22(13). 857–876. 210 indexed citations
14.
Welte, R, J.D. Bos, L van Alphen, et al.. (2004). Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine. 23(4). 470–479. 36 indexed citations
15.
Postma, Maarten J., R Welte, & Servaas A. Morré. (2002). Cost-effectiveness of widespread screening for Chlamydia trachomatis. Expert Opinion on Pharmacotherapy. 3(10). 1443–1450. 3 indexed citations
16.
Postma, Maarten J., et al.. (2001). Cost-Effectiveness of Partner Pharmacotherapy in Screening Women for Asymptomatic Infection with Chlamydia Trachomatis. Value in Health. 4(3). 266–275. 23 indexed citations
17.
18.
Kretzschmar, Mirjam, R Welte, Anneke van den Hoek, & Maarten J. Postma. (2001). Comparative Model-based Analysis of Screening Programs for Chlamydia trachomatis Infections. American Journal of Epidemiology. 153(1). 90–101. 97 indexed citations
19.
Welte, R, H.‐H. König, & Reiner Leidl. (2000). Tobacco. The Costs of Health Damage and Productivity Losses Attributable to Cigarette Smoking in Germany. SSRN Electronic Journal. 1 indexed citations
20.
Postma, Maarten J., et al.. (2000). Screening for asymptomatic infection with Chlamydia trachomatis in pregnancy; favourable cost-effectiveness if prevalence is 3% or more.. Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank. 144(49). 2350–2354. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Concepción Carratalá‐Munuera Breakdown of academic impact, for papers by Yagob Al-Mazrou Breakdown of academic impact, for papers by Fred Were Breakdown of academic impact, for papers by Helen McDonald Breakdown of academic impact, for papers by Ashley B. Coffield Breakdown of academic impact, for papers by Ramón Martínez Breakdown of academic impact, for papers by Mary Linehan Breakdown of academic impact, for papers by Charles Stoecker Breakdown of academic impact, for papers by Dan Ewald Breakdown of academic impact, for papers by Daniel J. Isaacman
Rankless by CCL
2026